Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GPR4 | P46093 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5820159 | 0.98 | OPRM1 (0.43) | OPRM1OPRD1OPRK1OPRL1GNAI3 | |
| SCHEMBL3026785 | 0.93 | OPRM1 (0.40) | OPRM1OPRD1OPRK1OPRL1GNAI3 | |
| SCHEMBL3262549 | 0.88 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1GNAI3 | |
| SCHEMBL26665511 | 0.84 | SLC6A4 (0.33) | GPR4KCNH2 | |
| SCHEMBL4437885 | 0.84 | — | — | |
| SCHEMBL17730835 | 0.81 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL17731291 | 0.81 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL17607210 | 0.81 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL1868334 | 0.81 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL17607279 | 0.81 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0083093-A2 | Process and intermediates of octahydrobenzofuro(3,2-e)isoquinolines | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-07-06 | — | — | EP | claimed |
| EP-3666757-A1 | PROCESS FOR PREPARING A PIPERIDIN-4-ONE | Karl-Franzens-Universität Graz (AT) | 2020-06-17 | — | — | EP | disclosed |
| CN-1989124-A | Quinazolin-4-yl- piperidine and cinnolin-4-yl- piperidine derivatives as pde10 inhibitors for the treatment of cns disorders | PFIZER (US) | 2007-06-27 | — | — | CN | disclosed |
| EP-1773805-A1 | QUINAZOLIN-4-YL-PIPERIDINE AND CINNOLIN-4-YL-PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Incorporated (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006011040-A1 | QUINAZOLIN-4-YL- PIPERIDINE AND CINNOLIN-4-YL- PIPERIDINE DERIVATIVES AS PDE10 INHIBITORS FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060019975-A1 | Novel piperidyl derivatives of quinazoline and isoquinoline | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| EP-1021185-A4 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-0721455-B9 | TETRAHYDROPYRIDINE-(OR 4-HYDROXYPIPERIDINE)ALKYLAZOLES HAVING AN AFFINITY FOR SIGMA AND/OR 5HT1A RECEPTORS | ESTEVE LABOR DR (ES) | 2005-04-20 | — | — | EP | disclosed |
| EP-1409476-B1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | GILMORE JEREMY (GB) | 2004-09-16 | — | — | US | disclosed |
| EP-0083093-A2 | Process and intermediates of octahydrobenzofuro(3,2-e)isoquinolines | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-07-06 | — | — | EP | disclosed |
| EP-0083093-A2 | Process and intermediates of octahydrobenzofuro(3,2-e)isoquinolines | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-07-06 | — | — | EP | disclosed |
| US-4364954-A | NEUROLEPTIC AGENT | WARNER-LAMBERT COMPANY (US) | 1982-12-21 | — | — | US | disclosed |
| US-4292321-A | 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof | WARNER-LAMBERT COMPANY (US) | 1981-09-29 | — | — | US | disclosed |
| US-4166853-A | Antihypertensive 7-trifluoromethyl-4-aminoquinolones | THE UPJOHN COMPANY (US) | 1979-09-04 | — | — | US | disclosed |
| US-4086234-A | Process for the preparation of tertiary amines | G. D. SEARLE & CO. (US) | 1978-04-25 | — | — | US | disclosed |
| US-4022786-A | PHARMACEUTICALS, CNS STIMULANT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-05-10 | — | — | US | disclosed |
| US-4022786-A | PHARMACEUTICALS, CNS STIMULANT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-05-10 | — | — | US | disclosed |
| US-4016280-A | 4,4-Diarylpiperidine compositions and use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
| US-4016280-A | 4,4-Diarylpiperidine compositions and use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | HTR1A, HTR5A, HTR1E | OPRM1 45/4885OPRD1 39/4885OPRK1 53/4885 |
| US-20060019975-A1 | Novel piperidyl derivatives of quinazoline and isoquinoline | PDE5A, PDE4A, PDE3A | OPRM1 2906/4885OPRD1 1215/4885OPRK1 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.